Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

Specimen Handling 465Magnetic Resonance Spectroscopy 351pembrolizumab 297Biopsy 251Carboplatin 235Cisplatin 199Cyclophosphamide 191Paclitaxel 167Nivolumab 159Gemcitabine 154Radiotherapy 129Bevacizumab 128Dexamethasone 115fludarabine 103Pemetrexed 102Fluorouracil 96Radiation 94Doxorubicin 94atezolizumab 93Docetaxel 93durvalumab 92venetoclax 91Rituximab 89Oxaliplatin 89Leucovorin 82Capecitabine 79Prednisone 78Lenalidomide 72X-Rays 69Etoposide 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ravulizumab × 30 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡